Sarepta Therapeutics (SRPT) Shorts Squeezed After Eteplirsen Receives FDA Approval
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Jabil falls after placing CEO on paid leave amid internal investigation
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- NVIDIA (NVDA) Shares Extend Drop To 10%, Erasing $212 Billion In Value - Bloomberg
- Tungray Technologies (TRSG) Prices 1.25M Share IPO at $4/sh
- Wells Fargo on Super Micro Computer (SMCI): 'No Positive Preannouncement
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer
September 20, 2016 1:18 PM EDTOppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).
Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More
Sarepta Therapeutic (SRPT) PT Raised to $66 at Wedbush
September 20, 2016 7:21 AM EDTWedbush analyst Heather Behanna reiterated an Outperform rating and boosted her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $66.00 (from $36.00) after the FDA approved eteplirsen.
Behanna commented, "In line with our expectations after FDA asked for new data, eteplirsen has received accelerated... More
RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target
September 19, 2016 1:52 PM EDTRBC Capital upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Sector Perform to Outperform with a price target of $83.00 (from $5.00).
Analyst Simos Simeonidis commented, "In one of the most perplexing regulatory decisions in recent history, FDA has granted accelerated approval to Sarepta's eteplirsen.... More
Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company
September 19, 2016 1:37 PM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $81.00 (from $47.00) following eteplirsen approval.
Messer commented, "The FDA has granted conditional approval to eteplirsen (Exondys 51) stating that data on dystrophin production was "reasonably... More
Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform
September 19, 2016 1:29 PM EDTLeerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).
Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary... More
Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval
September 19, 2016 1:08 PM EDTOppenheimer analyst Michelle Gilson reiterated an Outperform rating and raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $76.00 (from $60.00) after the FDA announced the approval of eteplirsen (EXONDYS 51) for the treatment of all boys with DMD amenable to Exon 51 skipping.
Gilson... More
Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%
September 19, 2016 11:21 AM EDTSarepta Therapeutics (NASDAQ: SRPT) trading at the highs of the session following FDA approval. Shares are up 90.7%
... MoreFDA Approves Sarepta Therapeutics' (SRPT) Eteplirsen
September 19, 2016 9:52 AM EDT(Updated - September 19, 2016 9:56 AM EDT)
The U.S. Food and Drug Administration today approved Sarepta Therapeutics' (Nasdaq: SRPT) Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.
Patients with a particular type of Duchenne muscular dystrophy will now have access to an approved treatment for this rare and devastating disease, said Janet Woodcock, M.D., director of the... More
Sarepta Therapeutics (SRPT) Granted FDA Accelerated Approval for Eteplirsen
September 19, 2016 9:51 AM EDTSarepta Therapeutics (NASDAQ: SRPT) surges higher on FDA approval for eteplirsen
Letter from FDA
... More